Moderna Cash Flow Statement
MRNA / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Moderna used $1.9B in operating cash flow and negative free cash flow of $2.1B in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.8B | -$3.6B | -$4.7B | -$747.0M | -$514.0M | -$747.0M | -$514.0M | -$384.7M | -$255.9M | -$216.2M |
| Depreciation & Amortization | $211.0M | $185.0M | $617.0M | $31.0M | $31.0M | $31.0M | $31.0M | $24.9M | $20.5M | $15.1M |
| Operating Cash Flow | -$1.9B | -$3.0B | -$3.1B | $2.0B | -$459.0M | $2.0B | -$459.0M | -$330.9M | -$331.5M | $66.7M |
| Capital Expenditures | $192.0M | $1.1B | $707.0M | $68.0M | $32.0M | $68.0M | $32.0M | $105.8M | $58.4M | $33.1M |
| Free Cash Flow | -$2.1B | -$4.1B | -$3.8B | $2.0B | -$491.0M | $2.0B | -$491.0M | -$436.6M | -$389.9M | $33.6M |
| Share Buybacks | $2.0M | $0 | $1.2B | $0 | $0 | $0 | $0 | - | - | - |
| FCF Margin | -106.2% | -125.3% | -55.9% | 244.0% | -818.3% | 244.0% | -818.3% | -323.3% | - | 31.0% |